Efficacy of Zinc Fortified Fermented Wheat Flour (EZAFFAW)

June 3, 2024 updated by: Dr Jai Kumar Das, Aga Khan University

EZAFFAW - Efficacy of Zinc Fortified Fermented Wheat Flour: Randomized Controlled Trial

Zinc is a pivotal micronutrient that participates in numerous essential metabolic pathways within the human body. Its multifaceted role makes the manifestations of zinc deficiency remarkably nonspecific and age-dependent. In children, zinc deficiency can manifest as growth retardation, cognitive impairment, recurrent infections, and other diverse symptoms. Adolescents and adults may experience fertility issues, work capacity impairment, and metabolic disorders due to zinc deficiency. Furthermore, zinc plays a crucial role in maintaining immune function, particularly in the elderly, where recurrent infections can be a notable outcome of deficiency. Given its fundamental importance, the potential benefits of zinc supplementation and fortification strategies have been explored, with some evidence indicating positive effects on health outcomes such as childhood mortality, diarrhea morbidity, and even risk factors for conditions like Type 2 Diabetes (T2DM) and cardiovascular disease (CVD). Understanding zinc's significance in these metabolic processes is vital for addressing deficiencies and improving public health.

A study is needed to assess the effect of various types of fermented and unfermented wheat flour flatbread and its impact on health including zinc status, anthropometric outcomes, risk of T2DM and CVD and morbidity on adolescent and adult females. The whole wheat flatbread trial would be ideal to inform policy as it is regularly consumed in Sindh as most people rely on chakki for wheat grinding and it is used commonly to make roti at home.

Study Overview

Detailed Description

STUDY DESIGN

This will be an individually randomized, double-blind efficacy trial in Mithi, District Tharparkar, Sindh, Pakistan. This district is among the most impoverished in Sindh, characterized by a tropical desert climate with extremely hot mornings. Approximately 87% of the population in Tharparkar lives below the poverty line. Due to its challenging demographics and environmental conditions, the region has endured severe droughts and faces the highest level of food insecurity among Sindh districts. It is concerning that 60% of children under five years suffer from stunting, 33.3% from wasting, and nearly 19.8% experience both conditions simultaneously. Additionally, approximately 40.4% of non-pregnant women of reproductive age are underweight. Tharparkar has been selected for this study due to its alarming rates of malnutrition and micronutrient deficiencies, making it an ideal location to assess the effectiveness of fortified wheat flour.

RESEARCH QUESTION

  • Primary Does consumption of whole wheat flatbread made with fermented and unfermented 'high zinc wheat' or with 'post-harvest zinc-fortified wheat flour' improve zinc status and metabolic health among adolescents (10-19 years) and adult women (20-40 years) at high risk of zinc deficiency and T2DM compared to 'low zinc' whole wheat flatbread?
  • Secondary Does an increase in bioavailable dietary zinc intake improve indicators for predicting the risk of T2DM in adolescents and adult women at high risk of zinc deficiency? SPECIFIC OBJECTIVES
  • Primary To evaluate the efficacy of whole wheat flatbread made with fermented and unfermented 'high zinc wheat' or post-harvest zinc-fortified wheat on zinc status/zinc deficiency and metabolic health among adolescents and adult women at high risk of zinc deficiency when compared to the 'low zinc' whole wheat flatbread.
  • Secondary To assess if an increase in bioavailable dietary zinc intake improves indicators for predicting the risk of T2DM in adolescents and adult women at high risk of zinc deficiency.

PARTICIPANTS The study will include adolescents (10-19 years) and adult women (20-40 years) INTERVENTION

Participants will be randomly divided into four groups according to the four-arm design in a 1:1:1:1 ratio. A total of 1000 participants would be randomly allocated to each of the groups in a 1:1:1:1 ratio.

  • Group 1: will receive fermented high zinc wheat flour flatbread
  • Group 2: will receive unfermented high zinc wheat flour flatbread
  • Group 3: will receive fortified (post-harvest) whole wheat flour flatbread
  • Group 4: will receive low zinc whole wheat flour flatbread

It would be a six-month intervention, where the participants would be given flatbread with a vegetable/pulse (daal) each day for six days a week for six months. On average, 2-3 flatbreads will be provided per participant (this was ascertained in the pilot activity). This would be provided at the school/college campus at lunch time i.e., at 1.30pm and all the participants enrolled in the study would be directly observed each day for the amount consumed and adult women would be provided meal at a community place.

OUTCOMES

Primary:

  • Serum zinc concentration
  • Zinc deficiency
  • HbA1C
  • Fasting blood glucose
  • Insulin levels
  • HOMA-IR (cut-off >2) (27)
  • Lipid profile (total cholesterol, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL); triglycerides (TGs))
  • Red blood cell membrane fatty acids concentrations

Secondary:

  • Anthropometric measurements:

    • Height
    • Weight
    • Mid upper arm circumference (MUAC)
    • Waist circumference
  • Body Mass Index (BMI) - Severe thinness, thinness, normal weight, overweight, obese
  • Blood Pressure
  • Anemia
  • School attendance/ performance
  • Dietary intakes through 24hr dietary recall.
  • Morbidity - Diarrhea, Acute respiratory infection (ARI) etc.

Compliance:

  • Number of days each participant had flatbread
  • Flatbread consumed (weight) each day

SAMPLE SIZE CALCULATION The study sample size was calculated based on an individually randomized four arm design on the primary outcome of mean serum zinc levels and HbA1c. The mean HbA1c taken was 5.62% (SD 1.96) and mean zinc was 79.5 µg/dL (SD 35.9) according to NNS-2018. The serum zinc data for the Tharparkar district was taken from NNS 2018, while there is no data on area specific estimates for T2DM and HbA1c. A recent national community-based survey conducted in 2019 found that the prevalence of diabetes (19.09%) and pre-diabetes (12.79%) in rural areas of Pakistan is high compared to the urban areas of Pakistan (diabetes: 15.75%; prediabetes: 9.89%) and the overall mean HbA1c was 5.62% (SD 1.96).

The sample size was calculated with a power of 0.8 and alpha of 0.05 to detect a difference of at least 0.12 effect size in the mean serum zinc levels between groups and to detect a 0.2 effect size in the mean HbA1c levels with a dropout rate of 10%.

The sample size calculated is 250 participants. A total of 1000 participants would be randomly allocated to each of the groups in a 1:1:1:1 ratio.

Baseline, midline, and end-line data collection.

All the participants will be assessed at baseline, and at endline. Data will be collected on socio-demographic factors, dietary intake through 24-hour dietary recall, anthropometry (weight, height, MUAC, waist circumference), blood pressures and blood samples for bio-chemical analysis including serum zinc levels, FBS, HbA1C, insulin at both baseline and endline, while lipid profile and RBC membrane fatty acids would be done at endline only. At midline, 24-hour dietary recalls, serum zinc, and HbA1C will be taken on a subset from each group. For morbidity and ARI, a two-week data collection will be carried out.

Study Type

Interventional

Enrollment (Actual)

1044

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sindh
      • Karachi, Sindh, Pakistan, 74800
        • Aga Khan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Adolescents aged 10-19 years
  • Adult women aged 20-40 years.
  • Wheat as a staple part of their diet

Exclusion Criteria:

  • Severe Malnutrition
  • Pregnant or Lactating
  • Chronic Diseases
  • Participation in Similar Programs
  • Individuals taking vitamin or mineral supplements at the time of enrollment
  • Planned Relocation from the study area within the next 6-7

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fermented High Zinc Wheat Flour Flatbread
Participants in this arm will receive fermented whole wheat flatbreads made from wheat variants with a high zinc content, ranging. These flatbreads are prepared through traditional fermentation methods.
  • Participants in this group will receive flatbreads made from fermented high zinc wheat flour.
  • The flatbreads will be prepared using traditional fermentation methods.
  • These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months.
Experimental: Unfermented High Zinc Wheat Flour Flatbread
Participants in this arm will receive unfermented whole wheat flatbreads made from wheat variants with a high zinc content. These flatbreads provide a source of bioavailable zinc without the fermentation process.
  • Participants in this group will receive flatbreads made from unfermented high zinc wheat flour,
  • The flatbreads will not undergo a fermentation process.
  • These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months.
Experimental: Fortified Wheat Flour flatbread
Participants in this arm will receive flatbreads made from whole wheat flour fortified post-harvest to contain a zinc content
  • Participants in this group will receive flatbreads made from whole wheat flour fortified post-harvest
  • These fortified flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months.
Active Comparator: Low Zinc Wheat flatbread
Participants in this arm will receive whole wheat flatbreads made from wheat variants with a low zinc content
  • Participants in this group will serve as the control group.
  • They will receive flatbreads made from whole wheat flour with a low zinc content
  • These low zinc flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months. six days a week over the course of six months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Zinc Status
Time Frame: Baseline and six months post intervention
The primary outcome is the measurement of serum zinc status (micrograms per deciliter (μg/dL) in participants. This includes assessing the concentration of zinc in serum samples. Changes in serum zinc levels will be compared between the four intervention groups.
Baseline and six months post intervention
Fasting Blood Glucose
Time Frame: Baseline and six months post-intervention.
This outcome assesses changes in participants' fasting blood glucose levels, measured in milligrams per deciliter (mg/dL). It aims to understand alterations in blood glucose levels resulting from flatbread interventions.
Baseline and six months post-intervention.
HbA1C Levels
Time Frame: Baseline and six months post-intervention.
This measure evaluates HbA1C levels, expressed as a percentage (%). It provides insights into long-term blood glucose control, helping assess the impact of dietary interventions.
Baseline and six months post-intervention.
Insulin Levels
Time Frame: Baseline and six months post-intervention.
This measure assesses participants' insulin levels, measured in microunits per milliliter (μU/mL). It helps in understanding changes in insulin sensitivity as a result of dietary interventions.
Baseline and six months post-intervention.
Lipid Profiles
Time Frame: Six months post-intervention.
This measure assesses participants' lipid profiles, with the unit of measure to be specified (e.g., milligrams per deciliter, mg/dL). It provides insights into changes in lipid levels and their potential effects on overall body composition due to dietary interventions.
Six months post-intervention.
Zinc Deficiency (%)
Time Frame: Baseline and six months post intervention
This primary outcome evaluates the prevalence of zinc deficiency among participants and it would be compared across the four groups.
Baseline and six months post intervention
Red blood cell membrane fatty acids concentrations
Time Frame: At six months post intervention
This outcome measures the red blood cell membrane fatty acids concentrations as a percentage (%) and This would be compared across the four groups.
At six months post intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Weight (kg)
Time Frame: Six months post intervention
This outcome assesses changes in participants' weight, measured in kilograms (kg), to understand alterations in their physical characteristics resulting from flatbread interventions.
Six months post intervention
Change in Height (m)
Time Frame: Six months post intervention
This measure evaluates changes in participants' height, measured in meters (m), to determine any variations in their physical stature due to dietary changes.
Six months post intervention
Change in BMI (kg/m²)
Time Frame: Six months post intervention
Body Mass Index (BMI) is calculated using weight (in kilograms) and height (in meters) and is measured in kg/m². This measure provides insights into participants' overall body composition and potential effects of dietary changes.
Six months post intervention
Acceptability and Adherence Assessment
Time Frame: Six months post intervention
Secondary outcomes focus on participants' satisfaction and adherence to dietary interventions, offering insights into the feasibility and acceptability of the intervention.
Six months post intervention
School Attendance and Academic Performance
Time Frame: Six months post intervention
This outcome aims to determine if the intervention resulted in better school attendance and academic performance (determined by school) among participants.
Six months post intervention
Morbidity
Time Frame: Six months post intervention
This outcome monitors the incidence of common health infections as diarrhea and acute respiratory infections and will be reported as a percentage (%).
Six months post intervention
Anemia
Time Frame: Six months post intervention
Anemia will be assessed through hemoglobin levels and will be reported as a percentage (%). This will determine whether there was a difference among the four groups.
Six months post intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jai K Das, Aga Khan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Actual)

May 31, 2024

Study Completion (Actual)

May 31, 2024

Study Registration Dates

First Submitted

September 22, 2023

First Submitted That Met QC Criteria

October 18, 2023

First Posted (Actual)

October 23, 2023

Study Record Updates

Last Update Posted (Estimated)

June 4, 2024

Last Update Submitted That Met QC Criteria

June 3, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation

Clinical Trials on Fermented High Zinc Wheat Flour Flatbread

Subscribe